| __timestamp | Agios Pharmaceuticals, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 406114000 |
| Thursday, January 1, 2015 | 35992000 | 449119000 |
| Friday, January 1, 2016 | 50714000 | 502892000 |
| Sunday, January 1, 2017 | 71124000 | 544156000 |
| Monday, January 1, 2018 | 114145000 | 683530000 |
| Tuesday, January 1, 2019 | 132034000 | 736942000 |
| Wednesday, January 1, 2020 | 149070000 | 854233000 |
| Friday, January 1, 2021 | 121445000 | 1451683000 |
| Saturday, January 1, 2022 | 121673000 | 1416967000 |
| Sunday, January 1, 2023 | 119903000 | 1343105000 |
| Monday, January 1, 2024 | 156784000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Jazz Pharmaceuticals plc and Agios Pharmaceuticals, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Jazz Pharmaceuticals consistently reported higher SG&A expenses, peaking at approximately $1.45 billion in 2021. This represents a staggering 257% increase from their 2014 figures. In contrast, Agios Pharmaceuticals, while also experiencing growth, maintained a more modest increase of around 526% over the same period, reaching about $120 million in 2023.
Jazz's higher expenses could indicate aggressive expansion or investment in marketing and administration, while Agios's more controlled spending might reflect a strategic focus on cost efficiency. As the pharmaceutical landscape evolves, these companies' ability to manage SG&A costs will be pivotal in determining their competitive edge.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. vs Jazz Pharmaceuticals plc: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Celldex Therapeutics, Inc.
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.